rs16861205 — ADIPOQ

Intronic ADIPOQ variant in LD with the promoter region; the minor A allele is associated with reduced circulating adiponectin in women and altered adiponectin dynamics during weight loss

See your personal result for ADIPOQ

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

The Adiponectin Intron — A Regulatory Tag for Metabolic Signalling

Adiponectin is the body's most abundant adipokine — a hormone secreted almost exclusively by adipose tissue11 hormone secreted almost exclusively by adipose tissue
it activates AMPK in muscle and liver, suppresses hepatic glucose output, and reduces vascular inflammation that acts as a master regulator of insulin sensitivity, lipid metabolism, and metabolic inflammation. Low circulating adiponectin is one of the most consistent biomarkers of metabolic dysfunction, predicting insulin resistance, type 2 diabetes, NAFLD, and cardiovascular disease independently of BMI. The ADIPOQ gene on chromosome 3 encodes this protein, and variation across the locus — particularly in two linkage disequilibrium blocks spanning the promoter and intron 1 — accounts for a meaningful portion of inter-individual differences in circulating adiponectin.

rs16861205 (chr3:186,843,845 GRCh38) sits in intron 1 of ADIPOQ, within the same linkage disequilibrium block as the promoter variant rs266729. Because rs16861205 and rs266729 are in LD, some of their phenotypic associations overlap — but studies that genotyped both simultaneously demonstrate that rs16861205 has independent contributions to adiponectin dynamics and body weight regulation.

The Mechanism

Intronic variants in ADIPOQ intron 1 may influence gene expression via several mechanisms: disruption of intronic regulatory elements22 regulatory elements
sequences within introns that bind transcription factors or modulate chromatin accessibility, altered pre-mRNA splicing kinetics, or tagging of functional variants in the local LD block. rs16861205 (G>A) is an intron variant catalogued in dbSNP Build 157 with no direct protein-coding consequence. Its functional role is thought to be regulatory — either through direct intronic regulatory activity or as a haplotype tag for the broader LD block 1, which contains the promoter.

The haplotype block containing rs16861205 and rs266729 spans the region approximately −14,811 to −4,120 base pairs relative to the ADIPOQ transcription start, covering the proximal promoter and intron 1. Variants in this block collectively influence ADIPOQ transcriptional activity and circulating adiponectin levels. Because rs16861205 participates in this block, its A allele may tag a local chromatin state that alters adiponectin expression — and the gender-specific effects observed in African American cohorts suggest the regulatory influence may be modulated by sex hormone signalling on ADIPOQ transcription.

The Evidence

The most informative data come from two independent cohorts. In the Finnish Diabetes Prevention Study33 Finnish Diabetes Prevention Study
n=507 overweight subjects with impaired glucose tolerance randomised to intensive lifestyle intervention vs control; Siitonen et al. 2011, rs16861205 was significantly associated with baseline body weight (GG carriers: 87.7 kg vs. GA/AA carriers: 84.3 kg, dominant model p=0.006) and with 4-year longitudinal weight change (additive p=0.028, dominant p=0.008). Strikingly, the A allele was associated with a greater increase in serum adiponectin concentrations over 4 years (additive p=0.040, dominant p=0.014), particularly among participants who lost weight during the first year of intervention. This suggests the A allele may reflect a distinct regulatory state in which adiponectin production is more responsive to weight loss.

A contrasting pattern was observed in the Jackson Heart Study44 Jackson Heart Study
n=2,968 African American adults (1,131 men, 1,837 women); Davis et al. 2015 — the largest population-specific analysis of rs16861205 to date. In women, the A allele was significantly associated with lower circulating adiponectin in the fully adjusted model (beta=−0.13, SE=0.05, p=0.003). No significant association was found in men (beta=−0.11, SE=0.061, p=0.074). A gender-stratified haplotype analysis Yansane et al. 201555 Yansane et al. 2015 confirmed that rs16861205 participates in a haplotype block (with rs6444174, rs1403697, and rs7641507) that shows significant effects on adiponectin in women but not men.

Taken together, the evidence points to rs16861205 as a variant that modulates adiponectin levels in a sex-specific and context-dependent way. The A allele appears to reduce baseline adiponectin in women (particularly African American women) while potentially conferring greater adiponectin responsiveness to weight loss intervention.

Practical Actions

For carriers of the A allele — particularly women — the primary concern is ensuring circulating adiponectin remains within the protective range (>8 µg/mL in women,

6 µg/mL in men). The most evidence-based dietary intervention for raising adiponectin is omega-3 fatty acids: a meta-analysis of 43 randomised trials with 3,434 participants found that EPA and DHA supplementation significantly increases adiponectin, with the largest effects in individuals with low baseline levels. Replacing dietary saturated fat with monounsaturated and polyunsaturated fats activates PPARgamma in adipocytes, stimulating ADIPOQ transcription regardless of intronic genotype.

For AA homozygotes and AG women with metabolic risk factors, measuring serum adiponectin directly provides the most actionable information — it reveals whether the regulatory variant is actually suppressing output to clinically meaningful levels, and it allows monitoring of dietary intervention response over time.

Interactions

rs16861205 is in the same LD block as rs266729, the well-characterised ADIPOQ promoter variant on the platform. The combined haplotype effect of LD block 1 (rs266729 + rs16861205) on adiponectin is likely stronger than either SNP alone, but the direction of the interaction requires haplotype-level analysis. Users carrying the rs266729 G risk allele alongside the rs16861205 A allele may have the most pronounced reduction in adiponectin signalling from this LD block.

rs182052 (ADIPOQ −10066G>A), also in the platform, shows a diet-genotype interaction with monounsaturated fat intake: rs182052 G/G homozygotes increase adiponectin on a high-MUFA diet while A-allele carriers do not — making fat quality a particularly relevant modifiable factor for the broader ADIPOQ LD block.

Nutrient Interactions

omega-3 fatty acids altered_metabolism

Genotype Interpretations

What each possible genotype means for this variant.

GG Common Adiponectin Intron Genotype Normal

Standard ADIPOQ intron 1 genotype — typical adiponectin regulation

You carry two copies of the G allele at rs16861205, the most common genotype at this position. About 74% of people carry this genotype globally. In the Finnish Diabetes Prevention Study, GG carriers had higher average body weight at baseline compared to A-allele carriers, but no differences in adiponectin trajectory were observed in subjects without significant weight loss. In African American cohorts, GG women showed higher circulating adiponectin than A-allele carriers. This genotype carries no specific actionable risk from this variant alone.

AG Adiponectin Intron Heterozygote Intermediate

One copy of the minor A allele — modestly altered adiponectin regulation, especially in women

rs16861205 sits in intron 1 of ADIPOQ within LD block 1, which also contains the promoter variant rs266729. The A allele at rs16861205 may tag a local chromatin or regulatory state that subtly modulates ADIPOQ transcription. The gender-specific signal in the Jackson Heart Study is consistent with sex hormone regulation of ADIPOQ — estrogen receptor elements in the ADIPOQ promoter region may interact with variants in LD block 1 differently across sexes. The heterozygous genotype likely confers a partial reduction in adiponectin in women, which is clinically meaningful primarily when combined with other metabolic risk factors such as central obesity, insulin resistance, or dyslipidaemia.

AA Minor Adiponectin Intron Genotype Decreased

Two copies of the minor A allele — reduced adiponectin regulation most pronounced in women

The AA genotype at rs16861205 represents two copies of the minor allele — doubling the regulatory perturbation relative to the AG genotype. In the Jackson Heart Study, the association between A allele dosage and lower adiponectin in women reached statistical significance, consistent with an additive dose-response model. While no large meta-analysis has isolated AA homozygotes specifically (the genotype is rare), the directionality of evidence from multiple populations supports treating this as the highest-effect genotype for adiponectin impairment at this locus.

rs16861205 is in LD block 1 with rs266729; AA homozygotes who also carry the rs266729 G risk allele may experience compounded reduction in ADIPOQ expression from both a promoter-level and an intron 1-level regulatory perturbation. This combination is particularly relevant for metabolic risk assessment.